Trials / Terminated
TerminatedNCT00040144
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (planned)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.
Detailed description
Evaluation of the safety and antiviral activity of 3 dose levels of ACH126, 433 over a 12-week treatment in the population is described.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACH126, 433 |
Timeline
- Start date
- 2002-07-01
- Completion
- 2003-05-01
- First posted
- 2002-06-25
- Last updated
- 2021-02-18
Locations
18 sites across 3 countries: United States, Canada, China
Source: ClinicalTrials.gov record NCT00040144. Inclusion in this directory is not an endorsement.